DSCSA Saleable Returns: New GS1 Guidance for Pharmacies
On September 23, 2026, GS1 US released new guidance on DSCSA saleable returns, outlining best practices for handling returned prescription drugs, verifying product identifiers, and maintaining accurate transaction records.
The guidance aims to improve consistency across the pharmaceutical supply chain and address challenges associated with product verification and electronic data exchange.
What Are DSCSA Saleable Returns?
Saleable returns are prescription drugs returned to a trading partner that may qualify for resale or redistribution.
Under the Drug Supply Chain Security Act (DSCSA), wholesale distributors must meet specific verification and transaction-record requirements before redistributing eligible returned products.
For pharmacies, this highlights the importance of maintaining accurate electronic tracing records for medications received from wholesalers.
What’s New in the GS1 Guidance?
The September 2026 guidance focuses on four key areas:
- Product Verification: Verifying serialized product identifiers to confirm the identity of returned medications.
- Transaction Records: Ensuring returned products can be associated with the required transaction information and transaction statements.
- Exception Management: Identifying and resolving discrepancies between physical products and electronic records.
- Returns Documentation: Establishing consistent procedures for tracking, reconciling, and documenting returned products.
Importantly, this guidance introduces industry best practices, not new federal DSCSA requirements.
What Does This Mean for Pharmacies?
Although the saleable-return verification requirements primarily affect wholesale distributors, pharmacies also play an important role in maintaining accurate drug tracing information.
Missing EPCIS data, incorrect product identifiers, or incomplete transaction records can complicate return processing and create additional work for trading partners.
Pharmacies should ensure their electronic tracing records are properly maintained, review their wholesalers’ return procedures, and establish processes for resolving data discrepancies.
Accurate Drug Traceability Starts With InfiniTrak
As DSCSA compliance continues to evolve, maintaining accessible and accurate electronic transaction records remains essential.
InfiniTrak’s integrated DSCSA compliance solution enables pharmacies to manage electronic product tracing, access EPCIS records, and maintain organized documentation through integrations with leading pharmacy management systems.
The latest GS1 guidance reinforces an important takeaway: reliable drug traceability doesn’t end when a shipment is received. It matters throughout the product’s journey, including returns.